pharmaceutical formulation
- H
Sai Parenteral IPO: Stock Performance at Market Debut
Sai Parenteral Shares List at Premium Despite Weak Market Sentiment New Delhi, April 2: Shares of Sai Parenteral, a diversified pharmaceutical formulation company, made a positive stock market debut on Thursday, listing at a premium of over 3 percent compared to its issue price, even as broader... - H
Pharmaceutical IPO Success: Sai Parenteral Raises Funds
Sai Parenteral IPO Fully Subscribed on Final Day Led by Institutional Demand IPO Sees Marginal Oversubscription with Strong Institutional Participation New Delhi, March 27 The initial public offering of Sai Parenteral, a diversified pharmaceutical formulation company, achieved full subscription...- Himanshu
- Thread
- contract development equity shares expansion fundraising global formulations initial public offering injectable products institutional investors investment ipo manufacturing organization nse data oral solid dosage formulations pharmaceutical formulation qib sai parenteral
- Replies: 0
- Forum: IPO
- H
Sai Parenteral IPO: 41% Subscription on Day 2
New Delhi, March 25 The initial public offering of Sai Parenteral's Ltd, a diversified pharmaceutical formulation company, saw 41 per cent subscription on the second day of the share sale on Wednesday.The IPO received bids for 30,82,788 shares against 75,22,486 shares on offer, according to...- Himanshu
- Thread
- anchor investors contract development and manufacturing organization equity shares global formulations initial public offering injectable products ipo subscription new delhi oral solid dosage formulations pharmaceutical formulation price band qualified institutional buyers retail individual investors sai parenteral's ltd
- Replies: 0
- Forum: Business
- H
Pharmaceutical IPO: Sai Parenteral's Initial Offering
Sai Parenteral’s IPO Receives 4% Subscription on First Day New Delhi, March 24 – The initial public offering (IPO) of Sai Parenteral’s Ltd, a diversified pharmaceutical formulation company, received a 4% subscription on Tuesday, the first day of bidding.Initial Bidding Figures According to...- Himanshu
- Thread
- capital markets contract development and manufacturing organization equity shares global formulations india initial public offering injectable products investment ipo subscription new delhi oral solid dosage formulations pharmaceutical formulation price band public offering sai parenteral
- Replies: 0
- Forum: Business
- H
Sai Parenteral Raises Over Rs 122 Cr in Pre-IPO Funding
New Delhi, March 23 Sai Parenteral's Ltd, a diversified pharmaceutical formulation company, raised over Rs 122 crore from anchor investors on Monday, a day before its initial public offering (IPO) opens for subscription.Morgan Stanley Asia (Singapore) Pte Ltd, Kotak Lifesciences Fund, Quant...- Himanshu
- Thread
- anchor investors capital raising contract development equity shares global formulations hyderabad india initial public offering injectable products ipo manufacturing organization new delhi oral solid dosage formulations pharmaceutical formulation sai parenteral
- Replies: 0
- Forum: Business
- H
Sai Parenteral’s IPO Price Band Set at ₹372 to ₹392 per Share, Targets ₹285 Crore Fresh Issue
Sai Parenteral’s IPO Price Band Set at ₹372 to ₹392 per Share, Targets ₹285 Crore Fresh Issue Company Files RHP with SEBI and Stock Exchanges Sai Parenteral’s Ltd, a diversified pharmaceutical formulation company, has announced the price band for its upcoming Initial Public Offering, setting it...- Himanshu
- Thread
- business expansion contract development and manufacturing organisation corporate finance equity shares financial global formulations initial public offering injectable products investment ipo oral solid dosage formulations pharmaceutical formulation red herring prospectus sai parenteral's ltd securities and exchange board of india stock exchange
- Replies: 0
- Forum: Business
- K
Biocon's Liraglutide Injection Gains USFDA Approval, Targeting Obesity Market
Biocon Secures US FDA Approval for Liraglutide Injection to Tap Growing GLP-1 Market Biocon Receives US FDA Nod for Complex Liraglutide Formulation Biocon Ltd announced on Tuesday that it has received approval from the US Food and Drug Administration for its complex formulation, Liraglutide...- Karthik
- Thread
- biocon ltd bse drug-device combination european union fda approval glp-1 receptor agonists glucagon-like peptide-1 liraglutide obesity treatment pharmaceutical formulation prefilled pens type 2 diabetes united states food and drug administration weight management
- Replies: 0
- Forum: Stocks